Inoviv Launches MasterKey™, A Customizable Platform for Multiplexed Targeted Protein Assays, Leveraging a Pre-Characterized Database of Thousands of Proteins

Inoviv Launches MasterKey™, A Customizable Platform for Multiplexed Targeted Protein Assays, Leveraging a Pre-Characterized Database of Thousands of Proteins

Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

Inoviv secures investment to expand quantitative proteomics product offerings to accelerate drug development pipelines

Inoviv secures investment to expand quantitative proteomics product offerings to accelerate drug development pipelines LONDON, January 30, 2024–(BUSINESS WIRE) –– Biomarker pioneer Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels. Building on […]